The burden of idiopathic pulmonary fibrosis: An unmet public health need

Augustine S. Lee, Isabella Mira-Avendano, Jay H Ryu, Craig E. Daniels

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease of unknown cause characterized by relentlessly progressive restrictive-ventilatory limitation, hypoxia, dyspnea, and cough. Both the incidence and prevalence of IPF appears to be increasing, with little impact on its dismal 3-year median survival, despite two decades of clinical trials. Increasingly recognized are the serious associated comorbid illnesses, including pulmonary hypertension, chronic obstructive pulmonary disease, gastroesophageal reflux disease, obstructive sleep apnea, obesity, lung cancer, and depression that further contribute to the substantial rise in the use of IPF-related healthcare resources. At present, lung transplantation remains the sole viable treatment for the few who qualify. Pharmacologic interventions targeting lung function and survival have remained largely disappointing, and very few investigations have specifically targeted comorbid conditions, symptoms, quality-of-life, and healthcare resource utilization. In reviewing the burden of illness associated with IPF, including the epidemiology, comorbidities, quality-of-life and the physical, psychosocial, and economic costs of this devastating disease, we hope to highlight some of the unmet medical needs associated with IPF, and encourage both public support and further investigations into these and other patient-centered outcomes and not just that of survival and lung function.

Original languageEnglish (US)
Pages (from-to)955-967
Number of pages13
JournalRespiratory Medicine
Volume108
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Idiopathic Pulmonary Fibrosis
Public Health
Cost of Illness
Survival
Quality of Life
Lung
Lung Transplantation
Quality of Health Care
Obstructive Sleep Apnea
Gastroesophageal Reflux
Cough
Pulmonary Hypertension
Dyspnea
Chronic Obstructive Pulmonary Disease
Lung Diseases
Comorbidity
Lung Neoplasms
Epidemiology
Obesity
Economics

Keywords

  • Burden of illness
  • Comorbid illness
  • Epidemiology
  • Health-related quality of life
  • Healthcare utilization
  • Idiopathic pulmonary fibrosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

The burden of idiopathic pulmonary fibrosis : An unmet public health need. / Lee, Augustine S.; Mira-Avendano, Isabella; Ryu, Jay H; Daniels, Craig E.

In: Respiratory Medicine, Vol. 108, No. 7, 2014, p. 955-967.

Research output: Contribution to journalArticle

Lee, Augustine S. ; Mira-Avendano, Isabella ; Ryu, Jay H ; Daniels, Craig E. / The burden of idiopathic pulmonary fibrosis : An unmet public health need. In: Respiratory Medicine. 2014 ; Vol. 108, No. 7. pp. 955-967.
@article{4996949914814ba09bca476c4dada9a5,
title = "The burden of idiopathic pulmonary fibrosis: An unmet public health need",
abstract = "Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease of unknown cause characterized by relentlessly progressive restrictive-ventilatory limitation, hypoxia, dyspnea, and cough. Both the incidence and prevalence of IPF appears to be increasing, with little impact on its dismal 3-year median survival, despite two decades of clinical trials. Increasingly recognized are the serious associated comorbid illnesses, including pulmonary hypertension, chronic obstructive pulmonary disease, gastroesophageal reflux disease, obstructive sleep apnea, obesity, lung cancer, and depression that further contribute to the substantial rise in the use of IPF-related healthcare resources. At present, lung transplantation remains the sole viable treatment for the few who qualify. Pharmacologic interventions targeting lung function and survival have remained largely disappointing, and very few investigations have specifically targeted comorbid conditions, symptoms, quality-of-life, and healthcare resource utilization. In reviewing the burden of illness associated with IPF, including the epidemiology, comorbidities, quality-of-life and the physical, psychosocial, and economic costs of this devastating disease, we hope to highlight some of the unmet medical needs associated with IPF, and encourage both public support and further investigations into these and other patient-centered outcomes and not just that of survival and lung function.",
keywords = "Burden of illness, Comorbid illness, Epidemiology, Health-related quality of life, Healthcare utilization, Idiopathic pulmonary fibrosis",
author = "Lee, {Augustine S.} and Isabella Mira-Avendano and Ryu, {Jay H} and Daniels, {Craig E.}",
year = "2014",
doi = "10.1016/j.rmed.2014.03.015",
language = "English (US)",
volume = "108",
pages = "955--967",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - The burden of idiopathic pulmonary fibrosis

T2 - An unmet public health need

AU - Lee, Augustine S.

AU - Mira-Avendano, Isabella

AU - Ryu, Jay H

AU - Daniels, Craig E.

PY - 2014

Y1 - 2014

N2 - Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease of unknown cause characterized by relentlessly progressive restrictive-ventilatory limitation, hypoxia, dyspnea, and cough. Both the incidence and prevalence of IPF appears to be increasing, with little impact on its dismal 3-year median survival, despite two decades of clinical trials. Increasingly recognized are the serious associated comorbid illnesses, including pulmonary hypertension, chronic obstructive pulmonary disease, gastroesophageal reflux disease, obstructive sleep apnea, obesity, lung cancer, and depression that further contribute to the substantial rise in the use of IPF-related healthcare resources. At present, lung transplantation remains the sole viable treatment for the few who qualify. Pharmacologic interventions targeting lung function and survival have remained largely disappointing, and very few investigations have specifically targeted comorbid conditions, symptoms, quality-of-life, and healthcare resource utilization. In reviewing the burden of illness associated with IPF, including the epidemiology, comorbidities, quality-of-life and the physical, psychosocial, and economic costs of this devastating disease, we hope to highlight some of the unmet medical needs associated with IPF, and encourage both public support and further investigations into these and other patient-centered outcomes and not just that of survival and lung function.

AB - Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease of unknown cause characterized by relentlessly progressive restrictive-ventilatory limitation, hypoxia, dyspnea, and cough. Both the incidence and prevalence of IPF appears to be increasing, with little impact on its dismal 3-year median survival, despite two decades of clinical trials. Increasingly recognized are the serious associated comorbid illnesses, including pulmonary hypertension, chronic obstructive pulmonary disease, gastroesophageal reflux disease, obstructive sleep apnea, obesity, lung cancer, and depression that further contribute to the substantial rise in the use of IPF-related healthcare resources. At present, lung transplantation remains the sole viable treatment for the few who qualify. Pharmacologic interventions targeting lung function and survival have remained largely disappointing, and very few investigations have specifically targeted comorbid conditions, symptoms, quality-of-life, and healthcare resource utilization. In reviewing the burden of illness associated with IPF, including the epidemiology, comorbidities, quality-of-life and the physical, psychosocial, and economic costs of this devastating disease, we hope to highlight some of the unmet medical needs associated with IPF, and encourage both public support and further investigations into these and other patient-centered outcomes and not just that of survival and lung function.

KW - Burden of illness

KW - Comorbid illness

KW - Epidemiology

KW - Health-related quality of life

KW - Healthcare utilization

KW - Idiopathic pulmonary fibrosis

UR - http://www.scopus.com/inward/record.url?scp=84902375258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902375258&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2014.03.015

DO - 10.1016/j.rmed.2014.03.015

M3 - Article

C2 - 24780718

AN - SCOPUS:84902375258

VL - 108

SP - 955

EP - 967

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 7

ER -